Search

Publication of EHA Annual General Meeting 2024 minutes

The 2024 EHA Annual General Meeting (AGM) took place in the vibrant city of Madrid, Spain, on June 14, 2024. Scheduled on Friday during the EHA Annual Congress, the meeting was once more in a hybrid format.

Read more

EHA-AHA hematology tutorial on Biology and Management of Myeloid Malignancies

In 2016, a new hematology center opened in Yerevan, which offers new services, enabling professionals working there to apply theoretical knowledge and advanced approaches in everyday practice.

Read more

Media

How to register for the EHA2025 Congress as a member of the press. Online press registration for EHA2025 will be open until 23:59 (CEST) on June 11, 2025.

Read more

European Hematology Association publishes new journal with Wolters Kluwer

The European Hematology Association, the largest Europe-based association of hematologists, launched its new journal HemaSphere with publisher Wolters Kluwer at the 22nd Annual Congress of EHA in Madrid.

Read more

A new form of inherited thrombocytopenia (ETV6-related thrombocytopenia, ETV6-RT): NEVER JUDGE A BOOK BY ITS COVER!

A new form of inherited thrombocytopenia (ETV6-related thrombocytopenia, ETV6-RT): NEVER JUDGE A BOOK BY ITS COVER!

We recently discovered a new form of an inherited deficiency of platelets (inherited thrombocytopenia-IT), which is caused by mutations in the ETV6-gene.

Read more

EHA-SLCH Hematology Tutorial on Myeloid Malignancies and MDS

Dates: February 8-9, 2019
Location: Colombo, Sri Lanka
Chairs: G Ossenkoppele, V Gunawardena, HW Goonasekera

After a successful first edition in 2017, EHA is organizing the second two-day tutorial in close collaboration with the Sri Lanka College of Haematologists (SLCH) on "Myeloid malignancies and MDS".…

Read more

Restoring Effective Anti-Tumor Response in Hodgkin Lymphoma with Nivolumab

Hodgkin Lymphoma typically affects young men and women in their 30s. Although it is highly curable with the current combination of chemo and radiation therapy, approximately 20% of patients will not be cured with first line regimens.

Read more